Suppr超能文献

比较手动病历审查和 ICD 索赔数据在评估免疫治疗相关不良事件中的应用。

Comparative assessment of manual chart review and ICD claims data in evaluating immunotherapy-related adverse events.

机构信息

Department of Internal Medicine, The Ohio State University, A450B Starling Loving Hall Columbus, Columbus, OH, 43210, USA.

Department of Biomedical Informatics and Center for Biostatistics, The Ohio State University, A450B Starling Loving Hall Columbus, Columbus, OH, 43210, USA.

出版信息

Cancer Immunol Immunother. 2021 Oct;70(10):2761-2769. doi: 10.1007/s00262-021-02880-0. Epub 2021 Feb 24.

Abstract

BACKGROUND

The aim of this retrospective study was to demonstrate that irAEs, specifically gastrointestinal and pulmonary, examined through International Classification of Disease (ICD) data leads to underrepresentation of true irAEs and overrepresentation of false irAEs, thereby concluding that ICD claims data are a poor approach to electronic health record (EHR) data mining for irAEs in immunotherapy clinical research.

METHODS

This retrospective analysis was conducted in 1,063 cancer patients who received ICIs between 2011 and 2017. We identified irAEs by manual review of medical records to determine the incidence of each of our endpoints, namely colitis, hepatitis, pneumonitis, other irAE, or no irAE. We then performed a secondary analysis utilizing ICD claims data alone using a broad range of symptom and disease-specific ICD codes representative of irAEs.

RESULTS

16% (n = 174/1,063) of the total study population was initially found to have either pneumonitis 3% (n = 37), colitis 7% (n = 81) or hepatitis 5% (n = 56) on manual review. Of these patients, 46% (n = 80/174) did not have ICD code evidence in the EHR reflecting their irAE. Of the total patients not found to have any irAEs during manual review, 61% (n = 459/748) of patients had ICD codes suggestive of possible irAE, yet were not identified as having an irAE during manual review.

DISCUSSION

Examining gastrointestinal and pulmonary irAEs through the International Classification of Disease (ICD) data leads to underrepresentation of true irAEs and overrepresentation of false irAEs.

摘要

背景

本回顾性研究旨在证明,通过国际疾病分类(ICD)数据检查的 irAE,特别是胃肠道和肺部 irAE,会导致真实 irAE 被低估,而假 irAE 被高估,因此得出结论,ICD 索赔数据是免疫治疗临床研究中从电子健康记录(EHR)数据中挖掘 irAE 的一种不佳方法。

方法

本回顾性分析纳入了 2011 年至 2017 年间接受 ICIs 治疗的 1063 例癌症患者。我们通过病历手动审查确定了 irAE 的发生率,以确定我们的各个终点,即结肠炎、肝炎、肺炎、其他 irAE 或无 irAE 的发生率。然后,我们使用 ICD 索赔数据进行了二次分析,使用了广泛的症状和疾病特异性 ICD 代码,代表了 irAE。

结果

在总研究人群中,最初有 16%(n=174/1063)被发现患有肺炎(3%,n=37)、结肠炎(7%,n=81)或肝炎(5%,n=56)。在这些患者中,46%(n=80/174)的患者的 EHR 中没有反映其 irAE 的 ICD 代码证据。在手动审查未发现任何 irAE 的患者中,61%(n=459/748)的患者的 ICD 代码提示可能存在 irAE,但在手动审查中未被识别为存在 irAE。

讨论

通过国际疾病分类(ICD)数据检查胃肠道和肺部 irAE 会导致真实 irAE 被低估,而假 irAE 被高估。

相似文献

1
Comparative assessment of manual chart review and ICD claims data in evaluating immunotherapy-related adverse events.
Cancer Immunol Immunother. 2021 Oct;70(10):2761-2769. doi: 10.1007/s00262-021-02880-0. Epub 2021 Feb 24.
3
Incidence and Outcome of Neurologic Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Patients With Melanoma.
Neurology. 2023 Dec 12;101(24):e2472-e2482. doi: 10.1212/WNL.0000000000207632. Epub 2023 Aug 31.
4
Delayed immune-related adverse events in long-responders of immunotherapy: a single-center experience.
Asia Pac J Clin Oncol. 2024 Aug;20(4):463-471. doi: 10.1111/ajco.14059. Epub 2024 Apr 12.
6
Patterns of Cutaneous and Noncutaneous Immune-Related Adverse Events Among Patients With Advanced Cancer.
JAMA Dermatol. 2021 May 1;157(5):577-582. doi: 10.1001/jamadermatol.2021.0326.
9
Dearth of ICD Codes for Complications of Immune Checkpoint Inhibitors Impedes Clinical Care and Research.
J Endocr Soc. 2023 Feb 1;7(4):bvad019. doi: 10.1210/jendso/bvad019. eCollection 2023 Feb 9.

引用本文的文献

1
Large Language Models for Adverse Drug Events: A Clinical Perspective.
J Clin Med. 2025 Aug 4;14(15):5490. doi: 10.3390/jcm14155490.
6
Role for Artificial Intelligence in the Detection of Immune-Related Adverse Events.
J Clin Oncol. 2024 Dec 10;42(35):4119-4122. doi: 10.1200/JCO-24-01570. Epub 2024 Oct 2.
8
Generalizability of machine learning methods in detecting adverse drug events from clinical narratives in electronic medical records.
Front Pharmacol. 2023 Jul 12;14:1218679. doi: 10.3389/fphar.2023.1218679. eCollection 2023.
9
Risk Factors for Immune Checkpoint Inhibitor Immunotherapy Toxicity Among Older Adults with Cancer.
Oncologist. 2023 Aug 3;28(8):e625-e632. doi: 10.1093/oncolo/oyad097.
10
Dearth of ICD Codes for Complications of Immune Checkpoint Inhibitors Impedes Clinical Care and Research.
J Endocr Soc. 2023 Feb 1;7(4):bvad019. doi: 10.1210/jendso/bvad019. eCollection 2023 Feb 9.

本文引用的文献

2
Association of immune-related pneumonitis with the efficacy of PD-1/PD-L1 inhibitors in non-small cell lung cancer.
Ther Adv Med Oncol. 2020 May 9;12:1758835920922033. doi: 10.1177/1758835920922033. eCollection 2020.
8
Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis.
J Clin Oncol. 2019 Oct 20;37(30):2738-2745. doi: 10.1200/JCO.19.00320. Epub 2019 Jun 4.
9
Immune checkpoint inhibitor-induced colitis: A comprehensive review.
World J Clin Cases. 2019 Feb 26;7(4):405-418. doi: 10.12998/wjcc.v7.i4.405.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验